What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.”In the company’s words, NCT06467344 on ClinicalTrials.gov
- Tested for
- Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
- Main trialPhase 1/2
- “This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.”In the company’s words, NCT06467344 on ClinicalTrials.gov
Other drugs for Stargardt Disease
Coming up1
- 1 Aug 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT06467344
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 1 Aug 2030 | Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026